Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products. Its principal products include Lexapro for the treatment of major depressive disorder in adults and adolescents, and generalized anxiety disorder in adults; Namenda for the treatment of moderate and severe Alzheimer's disease; Bystolic for the treatment of hypertension; Savella for the management of fibromyalgia; and Teflaro, a hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. The company is also developing various products, including Linaclotide that is in Phase III clinical trials for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation; Aclidinium, which is in Phase III clinical trials for the treatment of chronic obstructive pulmonary disease (COPD); and Cariprazine that is in Phase III clinical trials for the treatment of schizophrenia, bipolar mania, and other psychiatric conditions. In addition, it is developing F2695, which is in Phase III clinical trials for the treatment of depression; Avibactam, a beta-lactamase inhibitor that is in Phase II clinical trials; GRT 6005, which completed Phase II clinical trials for the treatment of moderate to severe chronic pain; TTP399 that completed Phase I clinical trial for the treatment of Type II diabetes; mGLuR1/5 Compounds for the treatment of anxiety, depression, and other central nervous system conditions; and LAS100977 that is in Phase II clinical trials for the treatment of asthma and COPD. Forest Laboratories, Inc. sells its products through its sales forces and independent distributors to physicians, pharmacies, hospitals, and managed care and other healthcare organizations. The company was founded in 1956 and is based in New York, New York.

Key Statistics